Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
nailKALM
Sydney, New South Wales, Australianailkalm.com.au ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
nailKALM is a healthcare company focused on the treatment of fungal nail infections (onychomycosis) using a proprietary bioactive ingredient called AMYCOT. AMYCOT is derived from a specific strain of Arthrospira maxima (Spirulina) and works by inhibiting the growth of dermatophytes that cause nail and skin infections. The company's lead product is a topical lotion clinically proven to improve nail appearance and health without the side effects often associated with systemic antifungal medications. nailKALM positions itself at the intersection of natural bioactive research and dermatological clinical efficacy.
- Therapeutic areas
- Infectious DiseasesDermatology
- Modalities
- BiologicTopical
- Industry
- Biotech
02
Partnerships
AFT Pharmaceuticals
Beyond the preview
Go deeper on nailKALM.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nailKALM.